Summa Equity buys Finnish antibody manufacturer HyTest
Summary
Summa Equity will become majority shareholder of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry.The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care.The company has great potential for continued growth, and we look forward to supporting the HyTest team on this journey,” says Tommi Unkuri, partner at Summa Equity.”Our goal since we started has been to improve health, by providing access to the latest research and technology in the arena of antibodies and antigens for diagnostic use to the market.With Summa Equity as owner, we will be able to take the next step in developing our company, for the benefit of our customers and patients,” says Maria Severina, CEO at HyTest.